KEYTRUDA is a prescription medicine used to treat a kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread, and tests positive for “PD-L1.”

KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Keytruda contains the drug pembrolizumab. It belongs to a class of drugs called PD-1 inhibitors. Keytruda is an immunotherapy drug, which means it tells certain parts of your immune system to attack cancer cells.

The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $11,115.04. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $22,230.08. * Most people will not pay the list price, although it may have an impact on your out-of-pocket costs.

Pembrolizumab (pronounced pem-bro-lih-zoo-mab) is a type of immunotherapy. It is also known by its brand name, Keytruda. You might have it as a treatment by itself or in combination with another treatment for a number of different cancer types.

Some patients can stay on KEYTRUDA for up to a year or two. Your doctor will decide how long you will be on treatment. Always talk to your doctor about what to expect while taking KEYTRUDA.

Pembrolizumab (pronounced pem-bro-lih-zoo-mab) is a type of immunotherapy. It is also known by its brand name, Keytruda. You might have it as a treatment by itself or in combination with another treatment for a number of different cancer types.

Keytruda (pembrolizumab) injection belongs to a class of medications called monoclonal antibodies. Pembrolizumab works by helping your immune system to slow or stop the growth and spread of cancer cells in the body.

The recommended dose of KEYTRUDA is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression [see Clinical Studies (14.2)].

Pembrolizumab (brand name: Keytruda) from Merck was first approved in September 2014 and since that time over 19 cancer uses have been approved by the FDA. It treats cancers ranging from advanced skin cancer, to bladder cancer to lung cancer.

KEYTRUDA is a type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA helps the immune system do what it was meant to do: detect and fight cancer cells.

by Drugs.com Keytruda is administered via a 30 min intravenous (IV) infusion every 3-6 weeks. A response to treatment is typically seen within 2-4 months of starting treatment with Keytruda, but the time it takes to work will vary based on cancer type and the stage of disease.